[HTML][HTML] Viral based vaccine TG4010 induces broadening of specific immune response and improves outcome in advanced NSCLC

C Tosch, B Bastien, L Barraud, B Grellier… - … for immunotherapy of …, 2017 - Springer
Background Advanced non-small cell lung cancer patients receiving TG4010, a therapeutic
viral vaccine encoding human Mucin 1 and interleukin-2 in addition to standard …

A unique anti-CD115 monoclonal antibody which inhibits osteolysis and skews human monocyte differentiation from M2-polarized macrophages toward dendritic cells

H Haegel, C Thioudellet, R Hallet, M Geist, T Menguy… - MAbs, 2013 - Taylor & Francis
Cancer progression has been associated with the presence of tumor-associated M2-
macrophages (M2-TAMs) able to inhibit anti-tumor immune responses. It is also often …

[HTML][HTML] Vaccinia virus shuffling: deVV5, a novel chimeric poxvirus with improved oncolytic potency

M Ricordel, J Foloppe, D Antoine, A Findeli, J Kempf… - Cancers, 2018 - mdpi.com
Oncolytic virus (OV) therapy has emerged as a promising approach for cancer treatment with
the potential to be less toxic and more efficient than classic cancer therapies. Various types …

3D modeling and characterization of the human CD115 monoclonal antibody H27K15 epitope and design of a chimeric CD115 target

B Grellier, B Grellier, F Le Pogam, F Le Pogam… - MAbs, 2014 - Taylor & Francis
The humanized monoclonal antibody H27K15 specifically targets human CD115, a type III
tyrosine kinase receptor involved in multiple cancers and inflammatory diseases. Binding of …

Phase 1 studies of personalized neoantigen vaccine TG4050 in ovarian carcinoma (OC) and head and neck squamous cell carcinoma (HNSCC).

JP Delord, MS Block, C Ottensmeier, G Colon-Otero… - 2022 - ascopubs.org
2637 Background: Mutation-associated neoantigens (MANAs) constitute attractive antigens
for the design of cancer vaccines. However, clinical implementation remains challenging …

PHASE I CLINICAL TRIAL WITH A NOVEL HCV THERAPEUTIC VACCINE TG4040: INTERIM RESULTS OF BIOMARKER AND IMMUNOMONITORING ANALYZES …

G Honnet, L Veron, D Olivier, B Grellier… - Hepatology, 2009 - journals.lww.com
Geraldine Honnet5, Laure Veron1, Delphine Olivier1, Benoît Grellier5, Bérangère Marie-
Bastien5, Edwige Bonfils5, Bastien Calmels5, Anne Fournillier1, Delphine Agathon5 …

Abstract CT182: Phase I trials of personalized cancer vaccine TG4050 in surgically treated high-risk head and neck squamous cell carcinoma (HNSCC) and relapsing …

MS Block, JP Delord, CH Ottensmeier, C Le Tourneau… - Cancer Research, 2022 - AACR
Background: Cancer mutations acquired during carcinogenesis are not subject to central
tolerance and thus, are cornerstone in cancer immunosurveillance. The use of mutation …

TG3003, an immunomodulatory anti-CD115 mAb targeting M2-macrophage polarization in the tumor microenvironment

H Haegel, C Ziller-Remy, L Barraud, JY Bonnefoy… - Cancer Research, 2015 - AACR
Cancer progression has been associated with the presence of tumor-associated M2-type
macrophages (M2-TAMs) able to inhibit anti-tumor immune responses, stimulate neo …

[PDF][PDF] Performance of neoantigen prediction for the design of TG4050, a patient specific neoantigen cancer vaccine

B Malone, C Tosch, B Grellier, K Onoue… - Proceedings of the …, 2020 - transgene.fr
BACKGROUND The development of therapeutic cancer vaccines to immunize against tumor
antigens constitutes a promising modality. Mutation-associated antigens are considered …

Abstract LB205: Feasibility and immunogenicity of adjuvant TG4050, a patient tailored cancer vaccine in head and neck and ovarian cancer

A Lalanne, C Jamet, CH Ottensmeier, JP Delord… - Cancer Research, 2023 - AACR
Abstract Background: Head and Neck (HNSCC) and Ovarian cancer (OC) are two
indications for which immunotherapy had limited impact so far. Current treatments achieve …